Global Protein Therapeutics Market - 2024-2031
Global Protein Therapeutics market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Protein therapeutics can treat various diseases such as immunological disorders, and hematological, genetic, and metabolic disorders. The modified versions of human proteins to treat diseases are typically referred to as protein therapeutics and it became a potential way to treat diseases like cancer. Due to increasing research and development, various therapeutic proteins are engineered by biopharmaceutical companies for the effective treatment of diseases.
Market Dynamics: Drivers & Restraints
Increasing Development of Protein therapeutic products
Protein therapeutics have a wide range of applications to treat several diseases like cancer, immunological, metabolic, hematological, and genetic disorders. Due to its wide range of applications, several companies are focused on researching and developing proteins and other molecules that target the proteins in the body. Increased focus on the development of protein therapeutic products by key companies is expected to drive the protein therapeutics market.
For instance, in November 2023, Eli Lilly and Company collaborated with Tokyo-based biotech PRISM Biolab to discover and develop small molecule inhibitors of protein-protein interactions.
Furthermore, in June 2023, IRBM signed a new agreement with Merck & Co. Inc. to combine scientific expertise in peptide design and synthesis and drug development capabilities. Also, in December 2023, C4 Therapeutics, Inc. entered into a license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs).
High Cost of Protein Bioengineering
Protein therapeutics production cost is very high due to the instability of the proteins. Amino acids as inputs to cell culture cost approximately $3 to $50 per kg, and growth factors cost $50,000 per gram, meaning that their costs can be half or more of the total production cost.
Protein production requires controlled conditions and due to its high denaturation nature, giving a final structure to the protein is a tedious task for biopharmaceutical companies. The costs of a single clinical trial can vary from $5 million for small, non-controlled orphan drug trials to $350 million for large controlled studies. These factors are expected to hamper the growth of the market.
Segment Analysisn
The global protein therapeutics market is segmented based on product, application, end-user and region.
Monoclonal Antibody Product Is Expected to Dominate Market
Monoclonal antibodies segment is expected to hold the largest share of the market due to the strategic developments by the companies. The developments include launches and pipeline products.
For instance, in August 2023, Regeneron Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority (BARDA) agreed to support clinical development, clinical manufacturing, and the regulatory licensure process of a next-generation COVID-19 monoclonal antibody therapy.
Furthermore, in January 2024, Oxitope Pharma and ArYY Therapeutics merged to form Calluna which raised $81m to advance the monoclonal antibody pipeline.
Geographical Analysis
North America is Expected to Dominate the Global Market
North America is expected to hold the largest share of the market due to the highest prevalence of cancer in this region. For instance, according to the American Cancer Society, colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Around 152,810 new cases and 53,010 deaths are estimated in 2024.
Furthermore, according to the American Cancer Society, In 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. The estimated numbers of new invasive cancer cases in the United States in 2024 are approximately 2,001,140 new cancer cases, the equivalent of about 5480 diagnoses each day.
Market Segmentation
By Product
• Blood Clotting Factors
• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Human Growth Hormone
• Follicle Stimulating Hormone
• Others
By Application
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Others
By End User
• Pharmaceutical Companies
• Research Organizations
• Academic Institutes
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In June 2023, Eli Lilly and Company agreed to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates.
• In December 2023, Deep Apple Therapeutics launched with $ 52 million in funding from Apple Tree Partners to develop small molecule drugs for treating metabolic disorders.
• In January 2024, Merck acquired Harpoon Therapeutics, Inc., a company focused on advancing cancer immunotherapy candidates and aims to enhance the oncology pipeline.
Competitive Landscape
The major global players in the protein therapeutics market include Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co, Inc, Novo Nordisk A/S, Pfizer Inc., Sanofi SA among others.
Why Purchase the Report?
• To visualize the global protein therapeutics market segmentation based on product, application, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of protein therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global protein therapeutics market report would provide approximately 57 tables, 66 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Product
- 3.2. Snippet by Application
- 3.3. Snippet by End User
- 3.4. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Development of Protein Therapeutic Products
- 4.1.1.2. YY
- 4.1.2. Restraints
- 4.1.2.1. High Cost of Protein Bioengineering
- 4.1.2.2. YY
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Patent Analysis
- 5.6. Pipeline Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Product
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
- 7.2. Blood Clotting Factors*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Monoclonal Antibodies
- 7.4. Insulin
- 7.5. Fusion Protein
- 7.6. Human Growth Hormone
- 7.7. Follicle Stimulating Hormone
- 7.8. Others
- 8. By Application
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
- 8.2. Cancer*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Hormonal Disorders
- 8.4. Genetic Disorders
- 8.5. Metabolic Disorders
- 8.6. Immunologic Disorders
- 8.7. Hematological Disorders
- 8.8. Others
- 9. By End User
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
- 9.2. Pharmaceutical Companies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Research Organizations
- 9.4. Academic Institutes
- 9.5. Others
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. UK
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 12. Company Profiles
- 12.1. Abbott Laboratories*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Amgen Inc.
- 12.3. Baxter International Inc.
- 12.4. Eli Lilly and Company
- 12.5. F. Hoffmann-La Roche Ltd.
- 12.6. Johnson & Johnson
- 12.7. Merck & Co, Inc
- 12.8. Novo Nordisk A/S
- 12.9. Pfizer Inc.
- 12.10. Sanofi SA
- LIST NOT EXHAUSTIVE
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook